Key Points
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020..
Oct 23 (Reuters) - Swiss pharmaceutical company Roche (ROG.S) has settled a patent lawsuit against U.S. biotech firm Biogen (BIIB.O) over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court...
Roche and its subsidiaries Genentech and Chugai Pharmaceutical (4519.T) jointly told the court without providing further details that they, Biogen and its manufacturer Bio-Thera (688177.SS) had agreed to settle the case...
Roche reported that it earned more than 2.7 billion Swiss francs - more than $3 billion based on current exchange rates - from worldwide sales of its biologic Actemra last year..
Roche's lawsuit, filed in July, said the biosimilar would infringe several patents related to the manufacture and use of its biologic drug...
